An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity

Vaccine

Volumn 22, Issue 23-24, 2004, Pages 3035-3044

  Ophorst, Olga J A E ^a   Kostense, Stefan ^a   Goudsmit, Jaap ^a   De Swart, Rik L ^b   Verhaagh, Sandra ^a   Zakhartchouk, Alexander ^c   Van Meijer, Marja ^a   Sprangers, Mieke ^a   Van Amerongen, Geert ^b   Yüksel, Selma ^b   Osterhaus, Albert D M E ^b   Havenga, Menzo J E ^a  

^a CRUCELL HOLLAND BV   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Dendritic cells; Pseudotyped vector; Recombinant adenovirus; Vaccination

Indexed keywords

ADENOVIRUS VECTOR; DRUG VEHICLE; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL GROWTH; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DRUG POTENCY; DRUG TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADENOVIRIDAE; ANIMALS; ANTIBODY FORMATION; CAPSID PROTEINS; CROSS REACTIONS; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HEMAGGLUTININS; HUMANS; INTERFERON TYPE II; MACACA FASCICULARIS; MEASLES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MONOCYTES; NEUTRALIZATION TESTS; TISSUE DISTRIBUTION; TRANSDUCTION, GENETIC; VACCINATION; VACCINES, DNA;

EID: 3843100497     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.02.011     Document Type: Article

References (50)

1. Coban C., Philipp M.T., Purcell J.E., Keister D.B., Okulate M., Martin D.S., et al. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect. Immun. 72(1):2004;253-259
2. Mascola J.R., Lewis M.G., VanCott T.C., Stiegler G., Katinger H., Seaman M., et al. Cellular immunity elicited by human immunodeficiency virus type 1/simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies. J. Virol. 77(19):2003;10348-10356
3. Premenko-Lanier M., Rota P., Rhodes G., Bellini W., McChesney M. Prior DNA vaccination does not interfere with the live-attenuated measles vaccine. Vaccine. 22(5-6):2004;763-766
4. Tsuji M., Bergmann C.C., Takita-Sonoda Y., Murata K., Rodrigues E.G., Nussenzweig R.S., et al. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J. Virol. 72(8):1998;6907-6910
5. Stittelaar K.J., Wyatt L.S., de Swart R.L., Vos H.W., Groen J., van Amerongen G., et al. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J. Virol. 74(9):2000;4236-4243
6. Prieur E., Gilbert S.C., Schneider J., Moore A.C., Sheu E.G., Goonetilleke N., et al. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proc. Natl. Acad. Sci. U.S.A. 101(1):2004;290-295. Epub 23 December 2003
7. Ferko B., Stasakova J., Sereinig S., Romanova J., Katinger D., Niebler B., et al. Hyperattenuated recombinant influenza A virus nonstructural-protein- encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J. Virol. 75(19):2001;8899-8908
8. Xin K.Q., Ooki T., Mizukami H., Hamajima K., Okudela K.H., et al. Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. Hum. Gene. Ther. 13(13):2002;1571-1581
9. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetentadenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415(6869):2002;331-335
10. Bruna-Romero O., Schmieg J., Del Val M., Buschle M., Tsuji M. The dendritic cell-specific chemokine, dendritic cell-derived CC chemokine 1, enhances protective cell-mediated immunity to murine malaria. J. Immunol. 170(6):2003;3195-3203
11. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109:2002;1519-1526
12. Zajac P., Oertli D., Marti W., Adamina M., Bolli M., Guller U., et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene. Ther. 14(16):2003;1497-1510. J Clin Oncol 2003;21(12):2247-53
13. Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 2003;21(12):2247-53.
14. Diao J., Smythe J.A., Smyth C., Rowe P.B., Alexander I.E. Human PBMC-derived dendritic cells transduced with an adenovirus vectorinduce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro. Gene. Ther. 6:1999;845-853
15. D'Ambrosio E., Del Grosso N., Chicca A., Midulla M. Neutralizing antibodies against 33 human adenoviruses in normal children in Rome. J. Hyg. (Lond.). 89:1982;155-161
16. Haase A.T., Pereira H.G. The purification of adenovirus neutralizing antibody: adenovirus type 5 hexon immunoadsorbent. J. Immunol. 108:1972;633-636
17. Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol. 170:2003;1416-1422
18. van Binnendijk R.S., Poelen M.C., van Amerongen G., de Vries P., Osterhaus A.D. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 175:1997;524-532
19. Stittelaar K.J., de Swart R.L., Osterhaus A.D. Vaccination against measles a neverending story. Expert Rev. Vac. 1:2002;151-159
20. Havenga M.J., Lemckert A.A., Ophorst O.J., van Meijer M., Germeraad W.T., Grimbergen J., et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 76:2002;4612-4620
21. Thomas R., Lipsky P.E. Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen-presenting cells. J. Immunol. 153:1994;4016-4028
22. Lafont B.A., Gloeckler L., D'Hautcourt J.L., Gut J.P., Aubertin A.M. One-round determination of seven leukocyte subsets in rhesus macaque blood by flow cytometry. Cytometry. 41:2000;193-202
23. de Swart R.L., Vos H.W., UytdeHaag F.G., Osterhaus A.D., van Binnendijk R.S. Measles virus fusion protein- and hemagglutinin-transfected cell lines are a sensitive tool for the detection of specific antibodies by a FACS-measured immunofluorescence assay. J. Virol. Methods. 71:1998;35-44
24. Rea D., Havenga M.J., van Den Assem M., Stut Muller R.P., Lemckert A., Hoeben R.C., et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J. Virol. 73:1999;10245-10253
25. Mercier S., Gahery-Segard H., Monteil M., Lengagne R., Guillet J.G., Eliot M., et al. Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product. J. Virol. 76:2002;2899-2911
26. De Vries I.J., Krooshoop D.J., Scharenborg N.M., Lesterhuis W.J., Diepstra J.H., van Muijen G.N., et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63:2003;12-17
27. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332
28. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., et al. Vaccination with mage-3A1 peptide-pulsed mature. J. Exp. Med. 190:1999;1669-1678
29. Lee K.J., Mao S., Sun C., Gao C., Blixt O., Arrues S., et al. Phage-display selection of a human single-chain fv antibody highly specific for melanoma and breast cancer cells using a chemoenzymatically synthesized G(M3)-carbohydrate antigen. J. Am. Chem. Soc. 124:2002;12439-12446
30. Wong C., Waibel R., Sheets M., Mach J.P., Finnern R. Human scFv antibody fragments specific for the epithelial tumour marker MUC-1, selected by phage display on living cells. Cancer Immunol. Immunother. 50:2001;93-101
31. Boots L.J., McKenna P.M., Arnold B.A., Keller P.M., Gorny M.K., Zolla-Pazner S., et al. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries. AIDS Res. Hum. Retroviruses. 13:1997;1549-1559
32. Gomez-Roman V.R., Cao C., Bai Y., Santamaria H., Acero G., Manout Charian K., et al. Phage-displayed mimotopes recognizing a biologically active anti-HIV-1 gp120 murine monoclonal antibody. J. Acquir. Immune. Defic. Syndr. 31:2002;147-153
33. Berger T.G., Feuerstein B., Strasser E., Hirsch U., Schreiner D., Schuler G., et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J. Immunol. Methods. 268:2002;131-140
34. Goxe B., Latour N., Chokri M., Abastado J.P., Salcedo M. Simplified method to generate large quantities of dendritic cells suitable for clinical applications. Immunol. Invest. 29:2000;319-336
35. Zhong L., Granelli-Piperno A., Choi Y., Steinman R.M. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur. J. Immunol. 29:1999;964-972
36. Havenga M.J., Lemckert A.A., Grimbergen J.M., Vogels R., Huisman L.G., Valerio D., et al. Improved adenovirus vectors for infection of cardiovascular tissues. J. Virol. 75:2001;3335-3342
37. Roelvink P.W., Lizonova A., Lee J.G., Li Y., Bergelson J.M., Finberg R.W., et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 72:1998;7909-7915
38. Mizuguchi H., Hayakawa T. Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene. 285:2002;69-77
39. Einfeld D.A., Schroeder R., Roelvink P.W., Lizonova A., King C.R., Kovesdi I., et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. 75:2001;11284-11291
40. van Deutekom J.C., Cao B., Pruchnic R., Wickham T.J., Kovesdi I., Huard J. Extended tropism of an adenoviral vector does not circumvent the maturation-dependent transducibility of mouse skeletal muscle. J. Gene. Med. 1:1999;393-399
41. Douglas J.T., Curiel D.T. Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors. Neuromuscul. Disord. 7:1997;284-298
42. Michou A.I., Santoro L., Christ M., Julliard V., Pavirani A., Mehtali M. Adenovirus-mediated gene transfer: influence of transgene. Gene. Ther. 4:1997;473-482
43. Levesvre P., Attema J., Lemckert A.A., Havenga M., van Bekkum D. Genetic heterogeneity in response to adenovirus gene therapy. BMC Mol. Biol. 4(1):2003;4
44. Fechner H., Haack A., Wang H., Wang X., Eizema K., Pauschinger M., et al. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 6:1999;1520-1535
45. Pimorady-Esfahani A., Grounds M.D., McMenamin P.G. Macrophages and dendritic cells in normal and regenerating murine skeletal muscle. Muscle Nerve. 20:1997;158-166
46. Molnar-Kimber K.L., Sterman D.H., Chang M., Kang E.H., ElBash M., Lanuti M., et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene. Ther. 9:1998;2121-2133
47. Chirmule N., Propert K., Magosin S., Qian Y., Qian R., Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6:1999;1574-1583
48. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune M-P, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of pre-existing adenovirus immunity. J Virol 2003;77(15):8263-71.
49. Youil R., Toner T.J., Su Q., Chen M., Tong A., Bett A.J., et al. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum. Gene Ther. 13:2002;311-320
50. Gall J.G., Crystal R.G., Falck-Pedersen E. Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J. Virol. 72:1998;10260-10264